Letetresgene autoleucel for treating synovial sarcoma and myxoid round cell liposarcoma

Letetresgene autoleucel is in clinical development for the treatment of advanced synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCLS) in children and adults. Both SS and MRCLS are two different types of soft tissue sarcomas, rare forms of cancer that develop in the tissues that connect, support, and surround other body structures and organs. Advanced SS or MRCLS means that the cancer has spread to other parts of the body. Currently there are limited therapies available for these patients, so there is a need to develop additional treatment options.